Melanoma of unknown primary shows an oncogenic pattern and clinical course of sun-exposed melanoma.

BACKGROUND

Melanoma of unknown primary (MUP) accounts for up to 10% of all cases of metastatic melanoma. The origin of MUP is unclear, and previous studies on the clinical course in comparison with cutaneous melanoma have reported varying results.

OBJECTIVES

The study was conducted to assess the oncogenic pattern of MUP and to compare the clinical course with that of melanoma of known cutaneous primary (MKP).

METHODS

Patients with MUP diagnosed between 1999 and 2022 were included in this cohort study from the prospective multicentre real-world DeCOG (German Dermatologic Cooperative Oncology Group) registry ADOREG and from the tumour database of the University Hospital Essen. For comparison, a cohort of consecutive patients with MKP with stage III or IV disease from the skin cancer centre Essen between 1999 and 2022 was used. The median follow-up was 3.5 years. Available tumour samples were genetically analysed using next-generation sequencing. Survival outcome adjusted for age, sex and tumour stage was compared between patients with MUP and those with MKP, using the Kaplan-Meier method.

RESULTS

In total, 727 patients with MUP and 587 with MKP were identified. Median age at first diagnosis was 62 years [interquartile range (IQR) 53-73] for MUP and 63 years (IQR 52-75) for MKP. Most patients were male, 448 (61.6%) with MUP and 330 (56.2%) with MKP. Of the 727 patients with MUP, 337 (46.4%) had stage III disease at first diagnosis. Overall survival (OS) at 48 months was 65% [95% confidence interval (CI) 61-69] for all patients with MUP and 68% (95% CI 64-72) for all patients with MKP. Survival analyses adjusted for age, sex and tumour stage showed comparable OS rates for patients with MUP and MKP. Genetic analyses of tumours from 110 patients with MUP detected C>T and CC→TT mutations as the most common nucleotide variations. Median tumour mutational burden was 5 mutations per Mb (95% CI 4-5). Activating BRAF V600E (c.620T>A) mutations were detected in 43 patients (39.1%), activating NRAS mutations in 37 (33.6%), RAC1 P29S mutations in 7 (6.3%) and TERT promoter mutations in 73 (66.4%) of the analysed tumour samples. No activating KIT mutations were detected.

CONCLUSIONS

The oncogenic pattern of MUP showed an ultraviolet mutation signature, suggesting an origin in sun-exposed areas. OS of MUP is comparable with that of MKP.